SCHEMBL3725918

NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)C(=O)[C](C(=O)O)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 10)

	gene	UniProt	supporting neighbours	confidence
▸	SLC15A2	Q16348	1/20	0.35

▸	C5AR1	P21730	2/20	0.35

▸	APLNR	P35414	2/20	0.35

▸	GHSR	Q92847	1/20	0.35

▸	NMT1	P30419	5/20	0.34

▸	NMT2	O60551	4/20	0.34

▸	CRHR1	P34998	1/20	0.33

▸	CRHR2	Q13324	1/20	0.33

▸	MC4R	P32245	1/20	0.33

▸	CALCR	P30988	1/20	0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL3731142	0.93	NMT1 (0.42)	C5AR1APLNRNMT1NMT2
SCHEMBL31041694	0.89	SLC15A2 (0.41)	SLC15A2C5AR1APLNRGHSR
SCHEMBL31041699	0.89	SLC15A2 (0.41)	SLC15A2C5AR1APLNRGHSR
SCHEMBL3727899	0.88	F2 (0.39)	SLC15A2C5AR1APLNRNMT1NMT2
SCHEMBL31041679	0.87	SLC15A2 (0.37)	SLC15A2C5AR1APLNRNMT1NMT2
SCHEMBL31041769	0.87	SLC15A2 (0.38)	SLC15A2C5AR1APLNRGHSR
SCHEMBL31041774	0.85	CALCR (0.38)	SLC15A2C5AR1APLNRNMT1NMT2
SCHEMBL31041731	0.85	SLC15A2 (0.38)	SLC15A2C5AR1APLNRNMT1NMT2
SCHEMBL31041733	0.85	SLC15A2 (0.38)	SLC15A2C5AR1APLNRNMT1NMT2
SCHEMBL31041750	0.83	CALCR (0.39)	SLC15A2C5AR1APLNRNMT1NMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20100173835-A1	Peptides for Treatment of Obesity	NOVO NORDISK A/S (DK)	2010-07-08	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100173835-A1	Peptides for Treatment of Obesity	MC4R, GIPR, MC3R	SLC15A2 2062/4885C5AR1 383/4885APLNR 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.